Reversal of bone loss in mice by nongenotropic signaling of sex steroids

Science

Volumn 298, Issue 5594, 2002, Pages 843-846

  Kousteni, S ^a   Chen, J R ^a   Bellido, T ^a   Han, L ^a   Ali, A A ^a   O'Brien, C A ^a   Plotkin, L ^a   Fu, Q ^a   Mancino, A T ^a   Wen, Y ^a   Vertino, A M ^a   Powers, C C ^a   Stewart, S A ^a   Ebert, R ^a   Parfitt, A M ^a   Weinstein, R S ^a   Jilka, R L ^a   Manolagas, S C ^a  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; HORMONES; TISSUE;

STEROIDS;

BONE;

ESTRADIOL; ESTROGEN; OSTEOCALCIN;

BONE; STEROID;

ANIMAL EXPERIMENT; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE STRENGTH; CONTROLLED STUDY; CORTICAL BONE; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; TRABECULAR BONE;

ANIMALS; APOPTOSIS; BODY WEIGHT; BONE AND BONES; BONE DENSITY; BREAST NEOPLASMS; CELL DIVISION; CELLS, CULTURED; COMPRESSIVE STRENGTH; DIHYDROTESTOSTERONE; ESTRADIOL; ESTRENES; FEMALE; HUMANS; MALE; MICE; ORCHIECTOMY; ORGAN SIZE; OSTEOBLASTS; OSTEOCALCIN; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS; OVARIECTOMY; PYRAZOLES; RECEPTORS, ESTROGEN; SEMINAL VESICLES; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; UTERUS;

ANIMALIA; MURINAE;

EID: 0037174675     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1074935     Document Type: Article

References (25)

1. J. G. Moggs, G. Orphanides, EMBO Rep. 2, 775 (2001).
2. N. J. McKenna, B. W. O'Malley, Cell 108, 465 (2002).
3. B. S. McEwen, S. E. Alves, Endocr. Rev. 20, 279 (1999).
4. E. Falkenstein, H. C. Tillmann, M. Christ, M. Feuring, M. Wehling, Pharmacol. Rev. 52, 513 (2000).
5. S. Kousteni et al., Cell 104, 719 (2001).
6. S. Kousteni et al., J. Bone Miner. Res. 17, S169 (2002).
7. Materials and Methods are available as supporting material on Science Online.
8. A. Samuels, M. J. Perry, J. H. Tobias, J. Bone Miner. Res. 14, 178 (1999).
9. A. T. Mancino et al., data not shown.
10. S. C. Manolagas, S. Kousteni, Endocrinology 142, 2200 (2001).
11. Z. Chen et al., J. Clin. Invest. 103, 401 (1999).
12. T. De Jager et al., J. Biol. Chem. 276, 27873 (2001).
13. J. L. Fitzpatrick et al., J. Neurochem. 82, 674 (2002).
14. H. M. Reichardt et al., Cell 93, 531 (1998).
15. P. J. Kushner et al., J. Steroid Biochem. Mol. Biol. 74, 311 (2000).
16. L. Grotewold, U. Rüther, EMBO J. 21, 966 (2002).
17. L. M. Boyden et al., N. Engl. J. Med. 346, 1513 (2002).
18. S. C. Manolagas, Endocr. Rev. 21, 115 (2000).
19. _, S. Kousteni, R. L. Jilka, Recent Prog. Horm. Res. 57, 385 (2002).
20. B. L Riggs, S. Khosla, L. J. Melton III, Endocr. Rev. 23, 279 (2002).
21. P. M. Doran, B. L. Riggs, E. J. Atkinson, S. Khosla, J. Bone Miner. Res. 16, 2118 (2001).
22. S. M. Ott, A. Oleksik, Y. Lu, K. Harper, P. Lips, J. Bone Miner. Res. 17, 341 (2002).
23. L. Mosca et al., Circulation 104, 499 (2001).
24. Writing Group for the Women's Health Initiative Investigators, JAMA 288, 321 (2002).
25. We thank B. S. and J. A. Katzenellenbogen for pyrazole, experimental assistance, and critical comments on the manuscript; P. K. Roberson and S. Korourian for expert advice; V. Lowe, R. Shelton, and J. Crawford for technical assistance; and M. Douglas for preparation of the manuscript. Supported by grants from NIH (P01-AG13918 to S.C.M. and KO2-AR02127 to T.B.); the Department of Veterans Affairs (merit and REAP awards to S.C.M.); and Anabonix Inc. (Little Rock, AR), which has a licensing agreement with the University of Arkansas for Medical Sciences to develop and commercialize anabolic drugs for osteoporosis, including the prototypic ligand described in this manuscript.